Advertisement
Organisation › Details
BioGeneration Ventures B.V. (BGV)
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. With a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies, BGV manages over €400 million of funds, and invests in areas where true scientific innovations, unmet medical needs, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to progress science and build successful companies and uses its experience to guide progress into clinical trials, leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. BGV is the early-stage focused platform partner of Forbion, a leading European life sciences venture capital fund with €3 billion in capital under management, and is based in Naarden, The Netherlands. For more information, please visit: http://www.biogenerationventures.com. The Fund V received an investment from the European Investment Fund, notably as part of the Venture Centre of Excellence initiative supported by the Health Compartment of the Sustainable Development Umbrella Fund, with the financial backing of the European Union under the European Fund for Strategic Investments (“EFSI”) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. *
Start | 2006-01-01 established | |
Industry | venture capital | |
Industry 2 | BIOTECH | |
Street | 2–35 Gooimeer | |
City | 1411 DC Naarden | |
Tel | +31-35-699-3000 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 400,000,000 (capital under management (2023) 2023-07-13) | |
* Document for »About Section«: BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for BioGeneration Ventures B.V. (BGV)
- [1] BioGeneration Ventures B.V.. (7/19/23). "Press Release: Dr. Markus Kalousek and Dr. Andrew Lightfoot Join BGV as Venture Partners". Amsterdam....
- [2] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
- [3] BioGeneration Ventures B.V.. (1/17/23). "Press Release: BGV Appoints Jaap de Bruin as FIRST Fund Investment Manager and Promotes Rianne Ellenbroek to Principal". Amsterdam....
- [4] BioGeneration Ventures B.V.. (11/8/22). "Press Release: BGV Appoints Elena Ritsou as Venture Partner and Andree Blaukat as Senior Advisor". Amsterdam....
- [5] BioGeneration Ventures B.V.. (9/14/21). "Press Release: BGV Expands Team with the Appointment of a Partner and Venture Partner". Naarden....
- [6] BioGeneration Ventures B.V.. (1/7/21). "Press Release: BioGeneration Ventures BGV IV Fund Closes at €140 Million". Naarden....
- [7] BioGeneration Ventures B.V.. (6/24/20). "Press Release: BioGeneration Ventures Closes BGV IV Fund at €105 Million". Naarden....
- [8] Azafaros B.V.. (7/23/18). "Press Release: Azafaros B.V. Secures Seed Funding to Develop New Treatments in Rare Metabolic Disorders". Leiden....
- [9] NorthSea Therapeutics B.V.. (12/12/17). "Press Release: NorthSea Therapeutics Secures €25 Million Funding for Clinical Development of Promising NASH Drug". Naarden....
- [10] BioGeneration Ventures B.V.. (6/27/17). "Press Release: BioGeneration Ventures Fund III Secures EUR 66m, Exceeding EUR 50m Target". Naarden....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top